While France wireless operator Iliad’s offer to acquire T-Mobile for $15 billion would likely face fewer regulatory obstacles than Sprint’s bid, unnamed sources say T-Mobile parent company Deutsche Telekom is unimpressed by the offer.
Iliad surprised the industry last week when it announced an offer to acquire T-Mobile, which has long been reported to be in merger discussions with Sprint to combine the US’s third- and fourth-place wireless operators. Iliad had offered to acquire a 56.6 percent stake in T-Mobile.
But according to one source, “this offer is not serious enough to walk away from Sprint/Softbank.” Softbank is the parent company of Sprint and is reported to be planning a formal acquisition bid for T-Mobile for about $32 billion.
But that plan is likely to face intense regulatory scrutiny. The merger would require approval from both the US Department of Justice as well as the Federal Communications Commission, and would need to overcome expected consumer advocate criticism as the nation’s media industry is headed towards a slew of multibillion-dollar deals.
Still, say reports, T-Mobile is likely to stick with a Sprint deal. Reports say the companies have agreed to a $2 billion breakup fee should the merger fail.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas